NUVL
Nuvalent, Inc. [NUVL] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
NUVL Stock Summary
Top 10 Correlated ETFs
NUVL
Top 10 Correlated Stocks
NUVL
In the News
NUVL Financial details
Company Rating
Neutral
Market Cap
4.2B
Income
-121.2M
Revenue
0
Book val./share
11.27
Cash/share
11.58
Dividend
-
Dividend %
-
Employees
92
Optionable
No
Shortable
Yes
Earnings
09 May 2024
P/E
-40.47
Forward P/E
-
PEG
-9.98
P/S
-
P/B
10.49
P/C
5.46
P/FCF
-52.22
Quick Ratio
14.2
Current Ratio
14.42
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-2.08
EPS next Y
-
EPS next Q
-
EPS this Y
46.62%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
5.08%
-
-
-
-
SMA20
-19.51%
SMA50
-15.38%
SMA100
8.2%
Inst Own
80.86%
Inst Trans
0.83%
ROA
-24%
ROE
-24%
ROC
-0.33%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
27.3-89.39
52W High
-28.98%
52W Low
+134.09%
RSI
29
Rel Volume
0.41
Avg Volume
434.61K
Volume
178.76K
Perf Week
-5.57%
Perf Month
-24.27%
Perf Quarter
17.15%
Perf Half Y
9.05%
-
-
-
-
Beta
1.296
-
-
Volatility
1.4%, 7.21%
Prev Close
-1.63%
Price
63.205
Change
-4.52%
NUVL Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 0 | 0 | |
| Net income per share | -0.24 | -0.3 | -0.96 | -1.48 | -2.17 | |
| Operating cash flow per share | -0.2 | -0.31 | -0.83 | -1.31 | -1.71 | |
| Free cash flow per share | -0.2 | -0.31 | -0.83 | -1.31 | -1.71 | |
| Cash per share | 0.06 | 0.21 | 5.97 | 9.51 | 12.36 | |
| Book value per share | -0.36 | -0.65 | 5.9 | 9.32 | 12.03 | |
| Tangible book value per share | -0.36 | -0.65 | 5.9 | 9.32 | 12.03 | |
| Share holders equity per share | -0.36 | -0.65 | 5.9 | 9.32 | 12.03 | |
| Interest debt per share | 0.11 | 0.09 | 0 | 0.09 | 0.4 | |
| Market cap | 905.32M | 905.32M | 919.58M | 1.48B | 4.28B | |
| Enterprise value | 904.48M | 897.23M | 851.06M | 1.24B | 3.95B | |
| P/E ratio | -76.66 | -62.2 | -19.85 | -20.17 | -33.95 | |
| Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
| POCF ratio | -93.92 | -60.56 | -22.99 | -22.77 | -42.96 | |
| PFCF ratio | -93.92 | -60.56 | -22.99 | -22.77 | -42.96 | |
| P/B Ratio | -52.46 | -28.9 | 3.23 | 3.19 | 6.12 | |
| PTB ratio | -52.46 | -28.9 | 3.23 | 3.19 | 6.12 | |
| EV to sales | 0 | 0 | 0 | 0 | 0 | |
| Enterprise value over EBITDA | -87.32 | -53.07 | -18.58 | -14.37 | -26.42 | |
| EV to operating cash flow | -93.84 | -60.02 | -21.28 | -19.04 | -39.6 | |
| EV to free cash flow | -93.84 | -60.02 | -21.28 | -19.04 | -39.6 | |
| Earnings yield | -0.01 | -0.02 | -0.05 | -0.05 | -0.03 | |
| Free cash flow yield | -0.01 | -0.02 | -0.04 | -0.04 | -0.02 | |
| Debt to equity | -0.31 | -0.13 | 0 | 0 | 0 | |
| Debt to assets | 1.6 | 0.39 | 0 | 0 | 0 | |
| Net debt to EBITDA | 0.08 | 0.48 | 1.5 | 2.81 | 2.24 | |
| Current ratio | 0.76 | 2.43 | 33.07 | 24.54 | 22.83 | |
| Interest coverage | 0 | 0 | 0 | -20.24 | -6.42 | |
| Income quality | 0.82 | 1.03 | 0.86 | 0.79 | 0.79 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 1.4 | 2.1 | 11.29 | 17.6 | 24.23 | |
| ROIC | 0.87 | 0.62 | -0.16 | -0.17 | -0.21 | |
| Return on tangible assets | -3.56 | -1.37 | -0.16 | -0.15 | -0.17 | |
| Graham Net | -0.36 | -0.66 | 5.78 | 9.11 | 11.82 | |
| Working capital | -1.04M | 6.27M | 281.84M | 458.51M | 694.67M | |
| Tangible asset value | -17.26M | -31.32M | 285.04M | 462.98M | 700.56M | |
| Net current asset value | -17.26M | -31.32M | 281.84M | 458.51M | 694.67M | |
| Invested capital | -0.31 | -0.13 | 0 | 0 | 0 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 0 | 987.5K | 2.07M | 5.04M | 8.23M | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0 | 0 | 0 | 0 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | 0.68 | 0.46 | -0.16 | -0.16 | -0.18 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 0 | 0 | |
| Net income per share | -0.37 | -0.36 | -0.51 | -0.59 | -0.62 | |
| Operating cash flow per share | -0.33 | -0.43 | -0.39 | -0.4 | -0.49 | |
| Free cash flow per share | -0.33 | -0.43 | -0.39 | -0.4 | -0.49 | |
| Cash per share | 8.81 | 7.94 | 7.58 | 7.24 | 11.58 | |
| Book value per share | 8.64 | 7.83 | 7.41 | 6.94 | 11.27 | |
| Tangible book value per share | 8.64 | 7.83 | 7.41 | 6.94 | 11.27 | |
| Share holders equity per share | 8.64 | 7.83 | 7.41 | 6.94 | 11.27 | |
| Interest debt per share | 0.06 | -0.09 | 0.09 | 0.09 | 0 | |
| Market cap | 1.6B | 1.48B | 2.4B | 2.62B | 4.58B | |
| Enterprise value | 1.35B | 1.39B | 2.33B | 2.54B | 4.24B | |
| P/E ratio | -20.19 | -18.33 | -20.61 | -19.5 | -29.88 | |
| Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
| POCF ratio | -89.81 | -60.6 | -108.34 | -114.2 | -151.48 | |
| PFCF ratio | -89.81 | -60.6 | -108.34 | -114.2 | -151.48 | |
| P/B Ratio | 3.45 | 3.33 | 5.69 | 6.63 | 6.53 | |
| PTB ratio | 3.45 | 3.33 | 5.69 | 6.63 | 6.53 | |
| EV to sales | 0 | 0 | 0 | 0 | 0 | |
| Enterprise value over EBITDA | -46.24 | -45.99 | -68.32 | -65.39 | -91.32 | |
| EV to operating cash flow | -76.21 | -56.91 | -105.14 | -110.35 | -140.38 | |
| EV to free cash flow | -76.21 | -56.91 | -105.14 | -110.35 | -140.38 | |
| Earnings yield | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | |
| Free cash flow yield | -0.01 | -0.02 | -0.01 | -0.01 | -0.01 | |
| Debt to equity | 0 | 0 | 0 | 0 | 0 | |
| Debt to assets | 0 | 0 | 0 | 0 | 0 | |
| Net debt to EBITDA | 8.25 | 2.98 | 2.08 | 2.28 | 7.22 | |
| Current ratio | 24.54 | 26.81 | 21.01 | 14.42 | 22.83 | |
| Interest coverage | -9.23 | 6.02 | -6.85 | -7.55 | 0 | |
| Income quality | 0.68 | 0.97 | 0.76 | 0.68 | 0.79 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 8.46 | 7.92 | 9.23 | 9.59 | 12.49 | |
| ROIC | -0.05 | -0.05 | -0.08 | -0.1 | -0.07 | |
| Return on tangible assets | -0.04 | -0.04 | -0.07 | -0.08 | -0.05 | |
| Graham Net | 8.44 | 7.64 | 7.22 | 6.73 | 11.07 | |
| Working capital | 458.51M | 439.27M | 416.2M | 390.67M | 694.67M | |
| Tangible asset value | 462.98M | 443.97M | 421.15M | 395.98M | 700.56M | |
| Net current asset value | 458.51M | 439.27M | 416.2M | 390.67M | 694.67M | |
| Invested capital | 0 | 0 | 0 | 0 | 0 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 5.91M | 6.81M | 7.28M | 8.95M | 9.53M | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0 | 0 | 0 | 0 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | -0.04 | -0.05 | -0.07 | -0.08 | -0.05 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
NUVL Frequently Asked Questions
What is Nuvalent, Inc. stock symbol ?
Nuvalent, Inc. is a US stock , located in Cambridge of Ma and trading under the symbol NUVL
What is Nuvalent, Inc. stock quote today ?
Nuvalent, Inc. stock price is $63.205 today.
Is Nuvalent, Inc. stock public?
Yes, Nuvalent, Inc. is a publicly traded company.
Company Profile
- Volume Average 434.61K
- Market Capitalization 4.2B
- Employee 92
- CEO Dr. James R. Porter Ph.D.
- Headquarters Cambridge,MA,US
- IPO Date 2021-07-29
-
Website
https://www.nuvalent.com 
Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; and NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, central nervous system-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under Phase I/II clinical trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
